Gene Data From HGNC: https://www.genenames.org/download/statistics-and-files/
Symbol:
MTAP
Name:
methylthioadenosine phosphorylase
Location:
09p21.3
Locus Group:
protein-coding gene
Gene Type:
Protein Coding
Locus Type:
gene with protein product
Clinical Trials Data: https://classic.clinicaltrials.gov/api/gui/ref/download_all
Clinical Studies
| NCT Number | Status | Brief Title | View |
|---|---|---|---|
| NCT01907607 | Efficacy and Safety of PD-0332991 in Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib | View | |
| NCT03666988 | First Time in Humans FTIH Study of GSK3368715 in Participants With Solid Tumors and Diffuse Large B-cell Lymphoma DLBCL | View | |
| NCT05335941 | A Phase 2 Study to Evaluate the Triplet Combination of Pemetrexed Plus AB928 Etrumadenant AB122 Zimberelimab in Patients With Previously Treated Advanced or Metastatic MTAP Deficient Urothelial Carcinoma | View | |
| NCT02693717 | Pemetrexed Disodium in Treating Patients With Previously Treated Metastatic Urothelial Cancer | View | |
| NCT03361358 | Pre-Screening Study to Identify MTAP Loss in Advanced Solid Tumors or Lymphoma | View | |
| NCT03435250 | Study of AG-270 in Participants With Advanced Solid Tumors or Lymphoma With MTAP Loss | View | |
| NCT06333951 | AMG 193 Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion Master Protocol | View | |
| NCT03744793 | Pemetrexed and Avelumab in Treating Patients with MTAP-Deficient Metastatic Urothelial Cancer | View | |
| NCT06630416 | Pemetrexed Response in Relation to Tumor Alterations of Gene Status for the Treatment of Patients With Metastatic Urothelial Bladder Cancer and Other Solid Tumors | View | |
| NCT04794699 | Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion | View | |
| NCT06130553 | A Study of AZD3470 a PRMT5 Inhibitor in Patients With MTAP Deficient AdvancedMetastatic Solid Tumours | View | |
| NCT05094336 | A Study of AMG 193 in Subjects With Advanced MTAP-null Solid Tumors | View | |
| NCT06360354 | A Study Evaluating AMG 193 in Combination With Other Therapies in Participants With Advanced Gastrointestinal Biliary Tract or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase MTAP-Deletion | View | |
| NCT05245500 | Phase 12 Study of MRTX1719 in Solid Tumors With MTAP Deletion | View | |
| NCT06593522 | A Phase 2 Study of AMG 193 in Participants With MTAP-deleted Advanced NSCLC | View | |
| NCT00075894 | Alanosine in Treating Patients With Progressive or Recurrent Malignant Gliomas | View | |
| NCT05732831 | Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors | View | |
| NCT06589596 | An Investigational Study of BGB-58067 in Participants With Advanced Solid Tumors | View | |
| NCT05975073 | A Phase 12 Study of AMG 193 in Combination With IDE397 in Participants With Advanced Methylthioadenosine Phosphorylase MTAP-Null Solid Tumors | View | |
| NCT06137144 | AZD3470 as Monotherapy and in Combination With Anticancer Agents in Participants With RelapsedRefractory Haematologic Malignancies | View | |
| NCT06188702 | S095035 in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of the Methylthioadenosine Phosphorylase MTAP Gene | View | |
| NCT06414460 | Study of ISM3412 in Participants With Locally AdvancedMetastatic Solid Tumors | View | |
| NCT05275478 | Safety and Tolerability of TNG908 in Patients With MTAP-deleted Solid Tumors | View | |
| NCT00062283 | Alanosine in Treating Patients With Cancer | View |